Literature DB >> 9517588

Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.

M W Ziegenhagen1, P Zabel, G Zissel, M Schlaak, J Müller-Quernheim.   

Abstract

It has been shown that interleukin 8 (IL-8) is increased in bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF) and there is increasing evidence that it is involved in the pathogenesis of this disease. To date, no data are available as to whether IL-8 is elevated in sera of IPF patients. We obtained sera from 42 patients with IPF and 20 healthy controls at time of BAL. From 20 of 42 patients with IPF and 12 of 20 controls BALF was available, enabling us to measure IL-8 in serum and BALF of the same time point. IL-8 was significantly elevated in serum (54.7 +/- 7.5 pg/ml, p < 0.0001) and BALF (715.7 +/- 112.4 pg/ml, p < 0.0001) of patients with IPF compared with controls (IL-8 in serum, 5.2 +/- 0.8 pg/ml; IL-8 in BALF, 67.3 +/- 9.7 pg/ml). We observed a significant positive correlation between IL-8 levels in BALF and percentage of BALF neutrophils (p < 0.001) and between serum IL-8 and BALF IL-8 levels (p < 0.005) in patients with IPF. Consequently, the serum IL-8 level correlated positively with the percentage of BAL neutrophils (p < 0.01), indicating that it may reflect the degree of neutrophilic alveolitis in IPF. Furthermore, the serum IL-8 level showed a negative correlation with important indicators of impairment of lung function (DL(CO), TLC, VC) and PaO2. In conclusion, we were able to demonstrate that the degree of neutrophilic alveolitis in IPF is reflected by increased serum levels of IL-8 and we suggest that the serological assessment of IL-8 may provide a useful parameter for clinicians in monitoring patients with IPF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517588     DOI: 10.1164/ajrccm.157.3.9705014

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

Review 3.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

4.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2009-04-10       Impact factor: 21.405

5.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

6.  MnTBAP Inhibits Bleomycin-Induced Pulmonary Fibrosis by Regulating VEGF and Wnt Signaling.

Authors:  Rajkumar Venkatadri; Anand Krishnan V Iyer; Vani Ramesh; Clayton Wright; Carlos A Castro; Juan S Yakisich; Neelam Azad
Journal:  J Cell Physiol       Date:  2016-09-26       Impact factor: 6.384

7.  Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis.

Authors:  Alyssa D Gregory; Corrine R Kliment; Heather E Metz; Kyoung-Hee Kim; Julia Kargl; Brittani A Agostini; Lauren T Crum; Elizabeth A Oczypok; Tim A Oury; A McGarry Houghton
Journal:  J Leukoc Biol       Date:  2015-03-05       Impact factor: 4.962

Review 8.  Occupational and environmental bronchiolar disorders.

Authors:  Kristin J Cummings; Kathleen Kreiss
Journal:  Semin Respir Crit Care Med       Date:  2015-05-29       Impact factor: 3.119

9.  Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.

Authors:  David N O'Dwyer; Shanna L Ashley; Stephen J Gurczynski; Meng Xia; Carol Wilke; Nicole R Falkowski; Katy C Norman; Kelly B Arnold; Gary B Huffnagle; Margaret L Salisbury; MeiLan K Han; Kevin R Flaherty; Eric S White; Fernando J Martinez; John R Erb-Downward; Susan Murray; Bethany B Moore; Robert P Dickson
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

10.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.

Authors:  H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.